Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic · Tablet · Updated Nov 11, 2026

Nevirapine 200 mg tablet price what pharmacies pay, and what you should

Pharmacies pay$4.41for 30 tablets · $0.1470 per tablet
Fair cash price$15.57cost + 15% + $10.50 fee
-0.1% in 4 weeks+9.6% in a yearLast change Oct 21, 2026: pharmacies' invoice prices changed (survey)

Is my price fair?

Check the price you were quoted

Type what the pharmacy asked for nevirapine 200 mg tablet and see the markup over what they pay.

How many?
$
Pharmacies payNADAC this week$4.41
Online cost-pluscost + 15% + fees$15.07
Fair cash pricecost + 15% + $10.50 fee$15.57
Your quotetype it above-
Pharmacies pay about $4.41 for 30 tablets. A fair cash price is around $15.57. Type your quote to see your markup.

A benchmark from public data, not a price offer or medical advice. Prices vary by pharmacy, insurance and discount programs.

Nevirapine 200 mg price history

What pharmacies pay for 30 tablets, weekly
$3.94$4.18$4.42$4.66DecFebAprJunAugOct
What pharmacies paid for 30 tablets of nevirapine 200 mg tablet over 52 weeks: from $4.02 on Nov 12, 2025 to $4.41 on Nov 11, 2026.
Now
$4.41
52-week low
$4.03
52-week high
$4.58
A year ago
$4.02

Why the price changed

EffectiveBeforeAfterChangeReason
Oct 21, 2026$0.1472$0.1470-0.1%pharmacies' invoice prices changed (survey)
Sep 23, 2026$0.1469$0.1472+0.3%pharmacies' invoice prices changed (survey)
Aug 19, 2026$0.1513$0.1469-3.0%pharmacies' invoice prices changed (survey)
Jul 22, 2026$0.1528$0.1513-0.9%pharmacies' invoice prices changed (survey)
Jun 17, 2026$0.1516$0.1528+0.8%pharmacies' invoice prices changed (survey)
May 20, 2026$0.1472$0.1516+2.9%pharmacies' invoice prices changed (survey)
Apr 22, 2026$0.1442$0.1472+2.1%pharmacies' invoice prices changed (survey)
Mar 18, 2026$0.1429$0.1442+0.9%pharmacies' invoice prices changed (survey)

Prices per tablet. Reasons are the ones the national survey gives: a survey rate change comes from pharmacies' own invoices; a published price change follows the maker's list price.

What did you pay for nevirapine 200 mg tablet? Share it.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Supply status: shortages & recalls

No shortage reportedChecked Nov 18, 2026
No ongoing recalls2 recalls on record, latest Dec 26, 2018

Recalls

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

Every manufacturer and package code

6 companies sell nevirapine 200 mg tablet under 11 package codes (NDCs). Pharmacies pay the same per tablet whichever maker they buy from - the national average is set for the generic as a group.

All 11 package codes

A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.

Questions to ask your pharmacist

  1. "What is your cash price, without insurance?" For low-cost generics it can be less than a copay.
  2. "Is a 90-day supply cheaper per tablet?" Dispensing fees are charged per fill, so fewer fills often cost less.
  3. "Do you match other pharmacies or accept discount cards?" Many do, if you ask.

These are questions, not advice. Never change how you take a medicine without talking to your prescriber or pharmacist.

Other nevirapine strengths and forms

Strength and formPer unitPharmacies pay4 weeks52 weeks
400 mg (24 hr) extended-release tablet$1.63$49.03 / 30 tablets+4.0%+7.6%
10 mg/mL oral suspensionNot priced this week

Official label & what changed

Last changedAugust 5, 2022
Version15 of 7
EffectiveAug 3, 2022
Read the label

These highlights do not include all the information needed to use NEVIRAPINE TABLETS safely and effectively. See full prescribing information for NEVIRAPINE TABLETS. NEVIRAPINE tablets, USP for oral use. Initial U.S. Approval: 1996

This drug has a boxed warning

WARNING: LIFE-THREATNING (INCLUDING FATAL) HEPATOTOXICITY and SKIN REACTIONS

HEPATOTOXICITY:

Severe, life-threatening, and in some cases fatal hepatotoxicity, particularly in the first 18 weeks, has been reported in patients treated with nevirapine. In some cases, patients presented with non-specific prodromal signs or symptoms of hepatitis and progressed to hepatic failure. These events are often associated with rash. Female gender and higher CD4

+ cell counts at initiation of therapy place patients at increased risk; women with CD4

+ cell counts greater than 250 cells/mm

3, including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. However, hepatotoxicity associated with nevirapine use can occur in both genders, all CD4

+ cell counts and at any time during treatment. Hepatic failure has also been reported in patients without HIV taking nevirapine for post-exposure prophylaxis (PEP). Use of nevirapine for occupational and non-occupational PEP is contraindicated

[see

Contraindications (4)]

. Patients with signs or symptoms of hepatitis, or with increased transaminases combined with rash or other systemic symptoms, must discontinue nevirapine and seek medical evaluation immediately

[see

Warnings and Precautions (5.1)]

.

SKIN REACTIONS:

Severe, life-threatening skin reactions, including fatal cases, have occurred in patients treated with nevirapine. These have included cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions characterized by rash, constitutional findings, and organ dysfunction. Patients developing signs or symptoms of severe skin reactions or hypersensitivity reactions must discontinue nevirapine and seek medical evaluation immediately. Transaminase levels should be checked immediately for all patients who develop a rash in the first 18 weeks of treatment. The 14-day lead-in period with nevirapine 200 mg daily dosing has been observed to decrease the incidence of rash and must be followed

[see

Warnings and Precautions (5.2)]

.

MONITORING FOR HEPATOTOXICITY AND SKIN REACTIONS:

Patients must be monitored intensively during the first 18 weeks of therapy with nevirapine to detect potentially life-threatening hepatotoxicity or skin reactions. Extra vigilance is warranted during the first 6 weeks of therapy, which is the period of greatest risk of these events. Do not restart nevirapine following clinical hepatitis, or transaminase elevations combined with rash or other systemic symptoms, or following severe skin rash or hypersensitivity reactions. In some cases, hepatic injury has progressed despite discontinuation of treatment.

WARNING: LIFE-THREATENING (INCLUDING FATAL) HEPATOTOXICITY and SKIN REACTIONS

See full prescribing information for complete boxed warning.

Fatal and non-fatal hepatotoxicity have been reported in patients taking nevirapine tablets. Discontinue immediately if clinical hepatitis or transaminase elevations combined with rash or other systemic symptoms occur. Do not restart nevirapine tablets after recovery. (

5.1)

Fatal and non-fatal skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions, have been reported. Discontinue immediately if severe skin reactions, hypersensitivity reactions, or any rash with systemic symptoms occur. Check transaminase levels immediately for all patients who develop a rash in the first 18 weeks of treatment. Do not restart nevirapine tablets after recovery. (

5.2)

Monitoring during the first 18 weeks of therapy is essential. Extra vigilance is warranted during the first 6 weeks of therapy, which is the period of greatest risk of these events. (

5.1,

5.2)

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Questions about nevirapine 200 mg tablet

How much does nevirapine 200 mg tablet cost without insurance?

Pharmacies pay about $4.41 for 30 tablets ($0.1470 per tablet) as of November 11, 2026. A fair cash price is about $15.57: that cost plus a 15% margin and a $10.50 dispensing fee. Online cost-plus pharmacies charge around $15.07 including shipping.

Is my price for nevirapine 200 mg tablet fair?

Compare it with the fair cash price of $15.57 for 30 tablets. Up to about $19.46 is fair; above $31.14 is high, and worth asking the pharmacy for its cash price or trying another pharmacy. Check your quote.

Is nevirapine 200 mg tablet getting more expensive?

Over the last four weeks the price pharmacies pay held steady. Over a year it rose 9.6%. See the 52-week chart.

Who makes nevirapine 200 mg tablet?

6 companies: Camber Pharmaceuticals, Inc., Macleods Pharmaceuticals Limited, Mylan Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Aurobindo Pharma Limited, Micro Labs Limited. See every package code.

Is nevirapine in shortage?

No shortage is reported right now. We check every day.

Has nevirapine been recalled?

2 recalls on record. Recalls name specific lots - check yours.

What does "pharmacies pay" mean?

It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.

Talk about nevirapine 200 mg tablet

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.